Comera Life Sciences Holdings, Inc. (CMRA) Research

Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on creating its own pipeline of innovative therapies. These treatments leverage its exclusive SQore formulation platform, engineered to transform intravenous (IV) biologic drugs into more convenient subcutaneous (SQ) injectable forms. Currently, the company is progressing two main product candidates: CLS-001, an early-stage "biobetter" designed to treat inflammatory bowel conditions like Crohn's and Ulcerative Colitis, and CLS-002, another preclinical biobetter aimed at diverse oncology indications. Established in 2014, Comera Life Sciences is headquartered in Woburn, Massachusetts.

Market snapshot

Symbol
CMRA
Price
$0.00
Day change
0.00%
Market cap
$3.1K
P/E ratio
-0.00x
52-week range
0.0001-0.0002
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Anthera Pharmaceuticals, Inc. (ANTH)
  • Cotinga Pharmaceuticals Inc. (COTQF)
  • FluoroPharma Medical, Inc. (FPMI)
  • GlobeImmune, Inc. (GBIM)
  • New Leaf Ventures Inc (NLVVF)
  • Neurobiological Technologies, Inc. (NTII)
  • Rebus Holdings, Inc. (RBSH)
  • Sienna Biopharmaceuticals, Inc. (SNNAQ)

Recent insider activity

  • Konar Shameek — P-Purchase (4090908 shares) on 2023-12-29
  • Konar Shameek — P-Purchase (0 shares) on 2023-12-29
  • Konar Shameek — trade (0 shares) on 2023-12-27
  • Konar Shameek — trade (513447 shares) on 2023-09-11
  • DENNY GEORGE P III — P-Purchase (3913526 shares) on 2023-12-29

Open Comera Life Sciences Holdings, Inc. (CMRA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.